BIRMINGHAM, Ala. and Pensacola, Fla. (December 8, 2022) – CIRCULOGENE is an innovative liquid biopsy company transforming precision medicine through the rapid and cost-effective delivery of actionable results and the only laboratory in the world that reports levels of the immunotherapy biomarker PD-L1 with a simple blood test. CIRCULOGENE is proud to announce the appointment of Robert “Bob” Gasparini, M.H.S., M.S., CG(ASCP), DLM(ASCP), to its Board of Directors. Prior to his retirement in 2021, Mr. Gasparini was a medical laboratory executive for over 20 years with proven success building multi-site laboratory infrastructure, troubleshooting technical issues across multiple testing platforms, and developing corporate-wide staff and client training programs. His specialized cancer testing expertise includes a focus in Cytogenetics and Fluorescence In-situ Hybridization (FISH).
At NeoGenomics, where he served for almost 18 years, Mr. Gasparini served as President, Chief Science Officer, and was on the Board of Directors. Over this time, he was instrumental in building high complexity specialized cancer testing laboratories and implementing cost-effective testing algorithms to improve patient care and provide cost savings for institutions and the US healthcare system. In addition, Mr. Gasparini was a driver in the development of NeoUniversity, the company’s educational infrastructure for internal team members and pathology clients.
Previously in his distinguished career, he was the Director of the Genetics Division for US Labs, the Molecular Marketing Manager for Ventana Medical Systems, and the Assistant Director of the Cytogenetics Laboratory for the Prenatal Diagnostic Center, an affiliate of Mass General Hospital. While at the Prenatal Diagnostic Center, Mr. Gasparini was also an Adjunct Professor at Harvard University. He is a licensed Clinical Laboratory Director and an accomplished author in the fields of Cytogenetics and Fluorescence In-Situ Hybridization (FISH) testing.
“We are thrilled to bring such a seasoned cancer diagnostics executive to our board,” said CIRCULOGENE President and CEO Mike Mullen. “With several new projects slated to be unveiled in the near future, Bob’s expertise and stellar track record will be instrumental in taking us to the next level.”
“I am excited to be working with such an innovative and forward-thinking company,” said Mr. Gasparini. “CIRCULOGENE’s processing of liquid biopsies has streamlined the collection process and reduced the time to therapy in a significant way, making a real difference for patients facing a cancer diagnosis.”
CIRCULOGENE provides comprehensive biomarker testing for a broad range of cancers allowing physicians to match patient results with specific therapies in just one week. The company has developed proprietary enrichment technology resulting in minimal genetic data loss. Their sequencing and qPCR methods can provide a full genomic load analysis to help clinicians select targeted therapies, monitor efficacy, and assess recurrence for cancer patients. Applying their proprietary liquid biopsy innovation for cfDNA and cfRNA, including PD-L1 and MSI detection, CIRCULOGENE can detect circulating germline and somatic mutations and RNA fusions.
CIRCULOGENE is a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) certified laboratory and a Verified Vendor for the federal System for Award Management. For more information, visit our website,connect with us on LinkedIn, Facebook, and Twitter, email email@example.com, or call us at 855-614-7083. Clinicians interested in ordering tests may also visit our contact page.